Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : NER1006 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2013
Lead Product(s) : Ganciclovir
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ganciclovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2010
Lead Product(s) : Ganciclovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Phase III
Recipient : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ferric Carboxymaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 27, 2010
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Phase III
Recipient : CSL Vifor
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
